Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People with HIV are at greater risk for hepatitis B but are less likely to get vaccinated and respond to vaccines.
Remdesivir (Veklury) is now approved for kids ages 28 days to 12 years.
Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.
Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
The new drugs must be used within a narrow window of time after developing symptoms.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Paxlovid dramatically reduced the risk of severe illness and death, but it must be started soon after developing symptoms.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
People under 50 who were cured of hepatitis C were at comparable risk to the general population.
Assessing patient-reported outcomes can support treatment for hard-to-reach populations.
The risk was lower in people who had achieved a sustained virological response compared with those who had not.
One link between coronaviruses (COVID-19) and the HIV drug Kaletra dates back to the 2003 outbreak of SARS.
Herpes simplex virus 1 (HSV1) may account for half of Alzheimer’s cases, according to a review of three recent studies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.